Antimicrobial resistance (AMR) represents a serious and growing threat to human health worldwide. It already kills 700 000 people globally every year, and that number could increase to 10 million by 2050. To combat AMR EU launched a new programme ND4BB, which features an unprecedented partnership between industry and academia, and it is supported by public and private funding. To boost early stage of antibiotic discovery (which is the most difficult stage), a new platform ENABLE was created with ND4BB program.
As a member of ENABLE consortium, we are involved in the development and optimization of molecules with the potential to become future antibacterial drug candidates.